NASDAQ:NKTR
Nektar Therapeutics
(NASDAQ:NKTR)
3.54
+0.08
(+2.31%)
As of 2022-05-27 Close (EST)
| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
stere • Stockfuse Continuum (US) • Mar 2021
Automatic trade executed by Stockfuse to ensure margin compliance.
ACTION
TICKER
SHARES
STATUS
ssnk001 • Stockfuse Continuum (US) • Mar 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
cgregs5798 • Wall Street bros and cocaine hoes • Feb 2020
Closing position
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
WSK • OLD|Aalto Investment Management Game (Spring 2020) • Jan 2020
Portfolio consists of 20 biotechnology/pharmaceutical corporations' stocks. Equal weighting | Passive buy and hold strategy, long term.
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. The stock price has been rather steady last 5 years. NKTR has a high beta of 2.58 adding risk and possibilities of revenue to our portfolio.
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS